Company news
enVVeno Medical Corporation news in 2025
enVVeno Medical Corporation's news releases, calls and decks from 2025, newest first.
enVVeno Medical (NASDAQ: NVNO) to Participate in a Live Virtual Investor CEO Connect Segment
November 26, 2025
enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve
November 13, 2025
enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 31, 2025
enVVeno Medical (NASDAQ: NVNO) Participates in Virtual Investor "What This Means" Segment
September 26, 2025
enVVeno Medical Updates Regulatory Status of VenoValve(R)
September 15, 2025
enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)
August 20, 2025
enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
August 15, 2025
Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency
August 6, 2025
enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company
August 4, 2025
enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 1, 2025
enVVeno Medical Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference
July 22, 2025
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
June 6, 2025
enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer
May 19, 2025
Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery
May 13, 2025
EnVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H25
May 2, 2025
enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24
May 1, 2025
VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium
April 23, 2025
enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment
April 16, 2025
The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium
March 31, 2025
EnVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25
March 3, 2025
enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25
February 28, 2025
enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
February 19, 2025
One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum
February 19, 2025